TACTIC Platform – ATG Therapeutics

TACTIC discovery platform

One biology. Two development opportunities.

TACTIC enables AtG to identify molecules with essential roles across tumor adaptation pathways and translate those discoveries into an integrated therapeutic + biomarker strategy.

Target the adaptive dependency.

Small-molecule programs designed to interfere with tumor adaptation biology.

Enrich for the right patients.

Patient enrichment and translational monitoring linked to the same underlying biology.

01 – Patient-derived tumor models

TACTIC uses patient-derived tumor models designed to closely mimic the biology and heterogeneity of human tumors.

02 – Controlled therapeutic pressure

We apply precisely controlled dose and duration of therapeutic pressure to reproduce the conditions that drive tumor adaptation and treatment escape.

03 – Adaptive response mapping

We interrogate the molecular changes induced by treatment to identify survival pathways and escape mechanisms activated by tumor cells.

04 – Advanced interrogation & filtering

TACTIC integrates data generated across the models with an advanced interrogation and filtering approach to prioritize factors most likely to play an essential role in tumor adaptation.

05 – Vulnerability prioritization

TACTIC identifies key factors essential for tumor survival across adptation pathways.

06 – Validation in human biospecimens

Prioritized factors are validated in human tumor samples from the biobank of our parent institution, strengthening their translational relevance.

07 – Therapeutic translation

The most compelling adaptation dependencies can be translated into therapeutic programs and biomarker strategies linked to the same underlying biology.

Pipeline

PROGRAM

TARGET

INDICATION

DISCOVERY PRE-CLINICAL IND-ENABLING CLINICAL

LEAD PROGRAM TA-1

TARGET Undisclosed

INDICATION RCC · CRC · HCC

Discovery Pre-clinical IND-enabling Clinical

TA-2

TARGET Undisclosed

INDICATION Prevalent solid tumors

Discovery Pre-clinical IND-enabling Clinical

TA-3

TARGET Undisclosed

INDICATION Prevalent solid tumors

Discovery Pre-clinical IND-enabling Clinical

Next Tumor Adaptation Vulnerability

TARGET Undisclosed

INDICATION Prevalent solid tumors

Discovery Pre-clinical IND-enabling Clinical

CANCER CELL 2005

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Foundational work demonstrating adaptive resistance to VEGF-pathway inhibition.

CANCER CELL 2009

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

CELL REPORTS 2016

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Patient-derived RCC models and clinical samples demonstrating treatment-induced metabolic adaptation.

Discover the adaptation. Identify the dependency. Translate it into therapy.

TACTIC provides AtG with a repeatable discovery engine to identify new tumor adaptation vulnerabilities and translate them into precision oncology programs.